Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)
Background In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost rad...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2010-02, Vol.32 (2), p.221-228 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 2 |
| container_start_page | 221 |
| container_title | Head & neck |
| container_volume | 32 |
| creator | Adelstein, David J. Moon, James Hanna, Ehab Giri, P. G. Shankar Mills, Glenn M. Wolf, Gregory T. Urba, Susan G. |
| description | Background
In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single‐agent cisplatin.
Methods
Two induction courses using docetaxel (75 mg/m2 on day 1), cisplatin (100 mg/m2 on day 1), and fluorouracil (1000 mg/m2/day continuous intravenous infusion days 1–4) were given, with an interval of 21 days. Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m2) on days 1 and 22 of radiation.
Results
There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease. At least 1 grade 3‐4 toxicity was experienced by 63 patients (85%) during induction. A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment. At least 1 grade 3‐4 toxicity was noted in 53 of the 58 patients (91%) evaluated for toxicity from concurrent chemoradiotherapy. Two patients died during induction, and 2 during chemoradiation. With a median follow‐up of 36 months (range, 14–50), the 2‐year and 3‐year overall survival estimates were 70% and 64%, with 2‐year and 3‐year progression‐free survival estimates of 66% and 61%, respectively.
Conclusions
Three‐drug induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin is toxic but feasible within a cooperative group. In this patient cohort with advanced head and neck squamous cell cancer, overall and progression‐free survivals were encouraging, justifying further study of this approach. © 2009 Wiley Periodicals, Inc. Head Neck, 2010 |
| doi_str_mv | 10.1002/hed.21179 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2967367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>744702703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5149-8bddd527c71a33b7e049668bd665985b022d3a5165a0e3ab4d8ecfe29a8589de3</originalsourceid><addsrcrecordid>eNqFkt9v0zAQxwMCsVF44B9Afplg0ro6dhwnPCBN3egqTexh_Hi0Lra7mLlxZifr-t_jtKXAA0KKHPvuc_f1nS9J3qT4NMWYTGqtTkma8vJpcpjiko8xzfizYZ_RMcU8O0hehvADY0zzjLxIDtKSMc4ZPnxycO6k7uBR2xMkTWgtdKY5QdAotLC98673II1FplG97IxrkKz10nW19tCu0cJZ61ZaoWqNQEpto7mLx0WMGmgYlol0jXRL00HTocq50CEPymx8G6XB33uvo3t_h6iI2riJxoBWpqsRqAdoZEwe7ntYuj6gqGdRrUFtsjRa3iE5IP4DOkM3ru_qlY5i11Hduts1msVyWtTWEDSaz1HnDVj0_gaTND9-lTxfgA369e4_Sr5-uvgyvRxfXc_m07OrsWRpVo6LSinFCJc8BUorrnFW5nm05jkrC1ZhQhQFluYMsKZQZarQcqFJCQUrSqXpKPm4zdv21VIrGevzYEXrzRL8Wjgw4m9PY2px6x4EKXNO4zdK3u0SeHffx_rE0oShE9Do2BTBs4xjwjH9P0lpgRkus0geb0npXQheL_b3SbEYRkzEERObEYvs2z8L-E3uZioCRzsAggQbR6GJr7rnCCEFJsUgOtlyK2P1-t-K4vLi_Jf0eBthQqcf9xHg70RsDGfi--eZwNm3K0ZyJqb0J32d_Yo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733805094</pqid></control><display><type>article</type><title>Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Adelstein, David J. ; Moon, James ; Hanna, Ehab ; Giri, P. G. Shankar ; Mills, Glenn M. ; Wolf, Gregory T. ; Urba, Susan G.</creator><creatorcontrib>Adelstein, David J. ; Moon, James ; Hanna, Ehab ; Giri, P. G. Shankar ; Mills, Glenn M. ; Wolf, Gregory T. ; Urba, Susan G.</creatorcontrib><description>Background
In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single‐agent cisplatin.
Methods
Two induction courses using docetaxel (75 mg/m2 on day 1), cisplatin (100 mg/m2 on day 1), and fluorouracil (1000 mg/m2/day continuous intravenous infusion days 1–4) were given, with an interval of 21 days. Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m2) on days 1 and 22 of radiation.
Results
There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease. At least 1 grade 3‐4 toxicity was experienced by 63 patients (85%) during induction. A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment. At least 1 grade 3‐4 toxicity was noted in 53 of the 58 patients (91%) evaluated for toxicity from concurrent chemoradiotherapy. Two patients died during induction, and 2 during chemoradiation. With a median follow‐up of 36 months (range, 14–50), the 2‐year and 3‐year overall survival estimates were 70% and 64%, with 2‐year and 3‐year progression‐free survival estimates of 66% and 61%, respectively.
Conclusions
Three‐drug induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin is toxic but feasible within a cooperative group. In this patient cohort with advanced head and neck squamous cell cancer, overall and progression‐free survivals were encouraging, justifying further study of this approach. © 2009 Wiley Periodicals, Inc. Head Neck, 2010</description><identifier>ISSN: 1043-3074</identifier><identifier>ISSN: 1097-0347</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.21179</identifier><identifier>PMID: 19557750</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - therapy ; chemoradiotherapy ; chemotherapy ; Cisplatin - therapeutic use ; concomitant ; Disease-Free Survival ; Docetaxel ; Dose Fractionation, Radiation ; Female ; Fluorouracil - administration & dosage ; Head and Neck Neoplasms - mortality ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - therapy ; Humans ; induction ; Male ; Medical sciences ; Middle Aged ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; radiation ; Radiotherapy, Adjuvant - adverse effects ; Radiotherapy, Adjuvant - methods ; Taxoids - administration & dosage ; Tumors</subject><ispartof>Head & neck, 2010-02, Vol.32 (2), p.221-228</ispartof><rights>Copyright © 2009 Wiley Periodicals, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5149-8bddd527c71a33b7e049668bd665985b022d3a5165a0e3ab4d8ecfe29a8589de3</citedby><cites>FETCH-LOGICAL-c5149-8bddd527c71a33b7e049668bd665985b022d3a5165a0e3ab4d8ecfe29a8589de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.21179$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.21179$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22280284$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19557750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adelstein, David J.</creatorcontrib><creatorcontrib>Moon, James</creatorcontrib><creatorcontrib>Hanna, Ehab</creatorcontrib><creatorcontrib>Giri, P. G. Shankar</creatorcontrib><creatorcontrib>Mills, Glenn M.</creatorcontrib><creatorcontrib>Wolf, Gregory T.</creatorcontrib><creatorcontrib>Urba, Susan G.</creatorcontrib><title>Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single‐agent cisplatin.
Methods
Two induction courses using docetaxel (75 mg/m2 on day 1), cisplatin (100 mg/m2 on day 1), and fluorouracil (1000 mg/m2/day continuous intravenous infusion days 1–4) were given, with an interval of 21 days. Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m2) on days 1 and 22 of radiation.
Results
There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease. At least 1 grade 3‐4 toxicity was experienced by 63 patients (85%) during induction. A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment. At least 1 grade 3‐4 toxicity was noted in 53 of the 58 patients (91%) evaluated for toxicity from concurrent chemoradiotherapy. Two patients died during induction, and 2 during chemoradiation. With a median follow‐up of 36 months (range, 14–50), the 2‐year and 3‐year overall survival estimates were 70% and 64%, with 2‐year and 3‐year progression‐free survival estimates of 66% and 61%, respectively.
Conclusions
Three‐drug induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin is toxic but feasible within a cooperative group. In this patient cohort with advanced head and neck squamous cell cancer, overall and progression‐free survivals were encouraging, justifying further study of this approach. © 2009 Wiley Periodicals, Inc. Head Neck, 2010</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>chemoradiotherapy</subject><subject>chemotherapy</subject><subject>Cisplatin - therapeutic use</subject><subject>concomitant</subject><subject>Disease-Free Survival</subject><subject>Docetaxel</subject><subject>Dose Fractionation, Radiation</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>induction</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>radiation</subject><subject>Radiotherapy, Adjuvant - adverse effects</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Taxoids - administration & dosage</subject><subject>Tumors</subject><issn>1043-3074</issn><issn>1097-0347</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt9v0zAQxwMCsVF44B9Afplg0ro6dhwnPCBN3egqTexh_Hi0Lra7mLlxZifr-t_jtKXAA0KKHPvuc_f1nS9J3qT4NMWYTGqtTkma8vJpcpjiko8xzfizYZ_RMcU8O0hehvADY0zzjLxIDtKSMc4ZPnxycO6k7uBR2xMkTWgtdKY5QdAotLC98673II1FplG97IxrkKz10nW19tCu0cJZ61ZaoWqNQEpto7mLx0WMGmgYlol0jXRL00HTocq50CEPymx8G6XB33uvo3t_h6iI2riJxoBWpqsRqAdoZEwe7ntYuj6gqGdRrUFtsjRa3iE5IP4DOkM3ru_qlY5i11Hduts1msVyWtTWEDSaz1HnDVj0_gaTND9-lTxfgA369e4_Sr5-uvgyvRxfXc_m07OrsWRpVo6LSinFCJc8BUorrnFW5nm05jkrC1ZhQhQFluYMsKZQZarQcqFJCQUrSqXpKPm4zdv21VIrGevzYEXrzRL8Wjgw4m9PY2px6x4EKXNO4zdK3u0SeHffx_rE0oShE9Do2BTBs4xjwjH9P0lpgRkus0geb0npXQheL_b3SbEYRkzEERObEYvs2z8L-E3uZioCRzsAggQbR6GJr7rnCCEFJsUgOtlyK2P1-t-K4vLi_Jf0eBthQqcf9xHg70RsDGfi--eZwNm3K0ZyJqb0J32d_Yo</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Adelstein, David J.</creator><creator>Moon, James</creator><creator>Hanna, Ehab</creator><creator>Giri, P. G. Shankar</creator><creator>Mills, Glenn M.</creator><creator>Wolf, Gregory T.</creator><creator>Urba, Susan G.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>201002</creationdate><title>Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)</title><author>Adelstein, David J. ; Moon, James ; Hanna, Ehab ; Giri, P. G. Shankar ; Mills, Glenn M. ; Wolf, Gregory T. ; Urba, Susan G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5149-8bddd527c71a33b7e049668bd665985b022d3a5165a0e3ab4d8ecfe29a8589de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>chemoradiotherapy</topic><topic>chemotherapy</topic><topic>Cisplatin - therapeutic use</topic><topic>concomitant</topic><topic>Disease-Free Survival</topic><topic>Docetaxel</topic><topic>Dose Fractionation, Radiation</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>induction</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>radiation</topic><topic>Radiotherapy, Adjuvant - adverse effects</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Taxoids - administration & dosage</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adelstein, David J.</creatorcontrib><creatorcontrib>Moon, James</creatorcontrib><creatorcontrib>Hanna, Ehab</creatorcontrib><creatorcontrib>Giri, P. G. Shankar</creatorcontrib><creatorcontrib>Mills, Glenn M.</creatorcontrib><creatorcontrib>Wolf, Gregory T.</creatorcontrib><creatorcontrib>Urba, Susan G.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adelstein, David J.</au><au>Moon, James</au><au>Hanna, Ehab</au><au>Giri, P. G. Shankar</au><au>Mills, Glenn M.</au><au>Wolf, Gregory T.</au><au>Urba, Susan G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2010-02</date><risdate>2010</risdate><volume>32</volume><issue>2</issue><spage>221</spage><epage>228</epage><pages>221-228</pages><issn>1043-3074</issn><issn>1097-0347</issn><eissn>1097-0347</eissn><abstract>Background
In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single‐agent cisplatin.
Methods
Two induction courses using docetaxel (75 mg/m2 on day 1), cisplatin (100 mg/m2 on day 1), and fluorouracil (1000 mg/m2/day continuous intravenous infusion days 1–4) were given, with an interval of 21 days. Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m2) on days 1 and 22 of radiation.
Results
There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease. At least 1 grade 3‐4 toxicity was experienced by 63 patients (85%) during induction. A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment. At least 1 grade 3‐4 toxicity was noted in 53 of the 58 patients (91%) evaluated for toxicity from concurrent chemoradiotherapy. Two patients died during induction, and 2 during chemoradiation. With a median follow‐up of 36 months (range, 14–50), the 2‐year and 3‐year overall survival estimates were 70% and 64%, with 2‐year and 3‐year progression‐free survival estimates of 66% and 61%, respectively.
Conclusions
Three‐drug induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin is toxic but feasible within a cooperative group. In this patient cohort with advanced head and neck squamous cell cancer, overall and progression‐free survivals were encouraging, justifying further study of this approach. © 2009 Wiley Periodicals, Inc. Head Neck, 2010</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19557750</pmid><doi>10.1002/hed.21179</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2010-02, Vol.32 (2), p.221-228 |
| issn | 1043-3074 1097-0347 1097-0347 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2967367 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - therapy chemoradiotherapy chemotherapy Cisplatin - therapeutic use concomitant Disease-Free Survival Docetaxel Dose Fractionation, Radiation Female Fluorouracil - administration & dosage Head and Neck Neoplasms - mortality Head and Neck Neoplasms - pathology Head and Neck Neoplasms - therapy Humans induction Male Medical sciences Middle Aged Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology radiation Radiotherapy, Adjuvant - adverse effects Radiotherapy, Adjuvant - methods Taxoids - administration & dosage Tumors |
| title | Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T04%3A00%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Docetaxel,%20cisplatin,%20and%20fluorouracil%20induction%20chemotherapy%20followed%20by%20accelerated%20fractionation/concomitant%20boost%20radiation%20and%20concurrent%20cisplatin%20in%20patients%20with%20advanced%20squamous%20cell%20head%20and%20neck%20cancer:%20A%20Southwest%20Oncology%20Group%20phase%20II%20trial%20(S0216)&rft.jtitle=Head%20&%20neck&rft.au=Adelstein,%20David%20J.&rft.date=2010-02&rft.volume=32&rft.issue=2&rft.spage=221&rft.epage=228&rft.pages=221-228&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.21179&rft_dat=%3Cproquest_pubme%3E744702703%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733805094&rft_id=info:pmid/19557750&rfr_iscdi=true |